loading page

Visual outcomes after bevacizumab-based therapy for optic pathway glioma
  • +2
  • Benjamin Siegel,
  • Daniel Nelson,
  • Jason Peragallo H,
  • Tobey MacDonald,
  • David Wolf S
Benjamin Siegel
Emory University Department of Pediatrics

Corresponding Author:[email protected]

Author Profile
Daniel Nelson
Emory University Emory Continuing Education
Author Profile
Jason Peragallo H
Emory University Emory Continuing Education
Author Profile
Tobey MacDonald
Emory University Department of Pediatrics
Author Profile
David Wolf S
Emory University Department of Pediatrics
Author Profile

Abstract

In optic pathway glioma (OPG), bevacizumab-based therapy (BBT) has promising effects on radiographic tumor burden, but impact on vision is less clear. This single-institution study characterized visual acuity (VA) and visual field (VF) outcomes in 17 pediatric OPG patients treated with BBT. VA was stable or improved in 14 patients. Nine patients had evaluable VF data, 6 of whom experienced stability or improvement. Among 6 patients with vision deterioration as a treatment indication, stable or improved was observed for both VA and VF in 5 patients. In summary, BBT was associated with favorable visual outcomes in most patients with OPG.
04 Apr 2023Submission Checks Completed
04 Apr 2023Assigned to Editor
04 Apr 2023Submitted to Pediatric Blood & Cancer
05 Apr 2023Review(s) Completed, Editorial Evaluation Pending
05 Apr 2023Reviewer(s) Assigned
11 May 2023Editorial Decision: Revise Major
10 Aug 20231st Revision Received
10 Aug 2023Submission Checks Completed
10 Aug 2023Assigned to Editor
10 Aug 2023Review(s) Completed, Editorial Evaluation Pending
10 Aug 2023Reviewer(s) Assigned
29 Aug 2023Editorial Decision: Accept